Adocia SA (FRA:A89)

Market Cap	145.35M
Revenue (ttm)	12.88M
Net Income (ttm)	-9.71M
Shares Out	n/a
EPS (ttm)	-0.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	98
Open	8.09
Previous Close	7.96
Day's Range	8.09 - 8.09
52-Week Range	3.00 - 11.40
Beta	n/a
RSI	43.30
Earnings Date	Mar 17, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and ra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 75
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: A89

Financial Performance

In 2024, Adocia's revenue was 12.12 million, an increase of 100.43% compared to the previous year's 6.05 million. Losses were -9.32 million, -55.95% less than in 2023.